排名前五的药物类型 | 数量 |
---|---|
单克隆抗体 | 2 |
抗体融合蛋白 | 2 |
融合蛋白 | 2 |
诊断用放射药物 | 1 |
核素偶联药物 | 1 |
作用机制 IL-2R调节剂 [+1] |
在研机构 |
原研机构 |
非在研适应症- |
最高研发阶段申请上市 |
首次获批国家/地区- |
首次获批日期- |
作用机制 EDB-FN抑制剂 [+1] |
原研机构 |
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期- |
靶点 |
作用机制 EDB-FN抑制剂 [+1] |
在研机构 |
原研机构 |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
开始日期2024-06-01 |
申办/合作机构 |
开始日期2023-12-19 |
申办/合作机构 Philogen SpA [+1] |
开始日期2023-04-27 |
申办/合作机构 |
Background Ovarian cancer is a significant health concern, necessitating the identification of potential diagnostic markers and novel therapeutic targets. This study presents, to the best of our knowledge, the first comparative immunohistochemical analysis of five tumor markers, namely the extra-domains A and B of fibronectin, fibroblast activation protein, carcinoembryonic antigen, and MUC16 in human epithelial ovarian cancer tissue samples. Methods Formalin-fixed paraffin-embedded human ovarian tissue sections were stained using previously validated antibodies to assess the percentage and intensity of marker expressions. Results Our results indicate a similar stromal pattern of expression for fibroblast activation protein, extra-domains A, and extra-domains B, with extra-domains A exhibiting the most intense staining. MUC16 was abundantly expressed on tumor cells of high-grade serous carcinoma samples, while carcinoembryonic antigen was not detected in this indication. Subsequent staining revealed that carcinoembryonic antigen was highly expressed on mucinous ovarian cancer specimens. With respect to clinical features, MUC16 and extra-domains A were found to be highly expressed in the most challenging scenarios namely platinum-resistant (100% and 50% respectively) and BRCA WT (75% and 45% respectively) patients. Conclusions The findings of this study highlight that MUC16, extra-domains B, and extra-domains A are attractive targets for the treatment of serous ovarian carcinoma, while carcinoembryonic antigen could be exploited for mucinous ovarian cancer. Clinical investigations are warranted to validate the potential of antibody-based therapies targeting these antigens in the context of ovarian cancer.